wasim

🫁 THE 10 MOST IMPORTANT LUNG CANCER TRIALS OF #ASCO26 🎯 TARGETED THERAPY MOVES EARLIER 1️⃣ LIBRETTO-432 (LBA3) Adjuvant selpercatinib in resected RET+ NSCLC Precision medicine officially enters curative-intent RET disease. 2️⃣ NeoADAURA Neoadjuvant osimertinib ± chemotherapy in EGFR-mutant NSCLC Targeted therapy keeps moving earlier. 3️⃣ CROWN 7-Year Update Lorlatinib vs crizotinib in ALK+ NSCLC Are we finally seeing a true survival plateau? 4️⃣ MARIPOSA Updated OS Amivantamab + lazertinib vs osimertinib The efficacy vs toxicity debate continues. 5️⃣ Beamion LUNG-1 CNS Cohort Zongertinib in HER2-mutant NSCLC Critical intracranial activity data. 🧬 FRONTLINE PRECISION EXPANSION 6️⃣ SUNVOZERTINIB 1L Frontline uncommon EGFR-mutant NSCLC A huge unmet-need population. 7️⃣ Olomorasib 1L Cohort Second-generation KRAS G12C inhibition moves upfront KRAS continues evolving rapidly. 🔥 IMMUNOLOGY & BISPECIFICS 8️⃣ HARMONi-6 (LBA4) Ivonescimab + chemo vs tislelizumab + chemo PD-1/VEGF bispecifics enter frontline squamous NSCLC. 9️⃣ DeLLphi-312 Tarlatamab in 1L ES-SCLC Potentially practice-changing if positive. 🔟 IMforte Subtype Analysis Can molecular SCLC subtypes finally guide maintenance therapy? Which thoracic abstract are you watching most closely? 👀 #LungCancer #LCSM #OncTwitter #MedTwitter #ASCO26 @ASCO @IASLC @myesmo @esmo_open @OncoAlert

@Arsenal BUKAYO 😍